Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Internal Medicine Physician in San Francisco, CA
NPI: 1154684777Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get M.D. Vadim's Phone Numberphone_androidMobile
Get M.D. Vadim's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
OH State Medical License
CA State Medical License
2018 - 2027
OH State Medical License
2015 - 2018
MI State Medical License
2012 - 2015
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Medical Oncology
Pritzker School of Medicine
pritzker.uchicago.edu
Medical School
Until 2012
Cleveland Clinic Foundation
Fellowship • Hematology and Medical Oncology
2015 - 2018
University of Michigan
Residency • Internal Medicine
2012 - 2015
University of Pennsylvania
BA • Cognitive Science
2003 - 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 179 | 493 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 39 | 39 |
| 3 | 36415Insertion of needle into vein for collection of blood sample | 14 | 47 |
Authors: Rohit Bose, David Oh, Jonathan Chou, Terence Friedlander, Eric Small, Rahul Aggarwal, Arpita Desai, Thomas Hope
Journal: Lancet Oncol
Authors: Carissa Chu, Maxwell Meng, Peter Black, Emily Chan, Jonathan Chou, Sima Porten, Terence Friedlander, Emily Chan, Raj Pruthi
Journal: Eur Urol Oncol
Publication Date: 2022-02-23
Authors: Mehmet Bilen, Arjun Balar, Maged Khalil, Mary Tagliaferri, Arlene Siefker-Radtke, David Chien
Journal: Future Oncol
Publication Date: 2020-09-17
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Collaborators: Merck Sharp & Dohme LLC, RemeGen Co., Ltd.
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: pembrolizumab, DRUG: gemcitabine, DRUG: disitamab vedotin
Lead Sponsor: Merck Sharp & Dohme LLC
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, COMBINATION_PRODUCT: EV, BIOLOGICAL: Coformulated favezelimab/pembrolizumab, BIOLOGICAL: Coformulated vibostolimab/pembrolizumab
Lead Sponsor: Vadim S Koshkin
Collaborators: Eli Lilly and Company, Prostate Cancer Foundation
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Lutetium Lu 177-PSMA-617
